IGC Pharma, Inc. furnished an updated investor presentation dated July 2026 as part of its Regulation FD disclosure. The company is a biopharmaceutical company focused on developing and commercializing product candidates like IGC-AD1.

IGC Pharma, Inc. entered into Stock Purchase Agreements with CEO Ram Mukunda and VP/PFO Claudia Grimaldi on June 30, 2026, to settle outstanding obligations totaling $1,154,210 through the issuance of 4,274,853 shares of common stock at $0.27 per share. The transactions, approved by independent directors, satisfied personal cash advances and other deferred amounts owed to the executives. IGC Pharma, Inc. is a pharmaceutical company.

IGC Pharma, Inc. entered into an amendment to extend its Master Loan and Security Agreement with O-Bank Co., Ltd. on June 5, 2026, maintaining a maximum aggregate limit of $12,000,000, with the facility fee increasing from $48,000 to $60,000.